Last 27 quarters of trend data · Healthcare · Oncology Biotech
Quarterly valuation ratios — annualised for comparability. YoY Δ shows same-quarter-prior-year change.
| Metric | TTM | Q2 '26 | Q1 '26 | Q4 '25 | Q3 '25 | Q2 '25 | Q1 '25 | Q4 '24 | Q3 '24 | Q2 '24 | Q1 '24 | Q4 '23 | Q3 '23 | Q2 '23 | Q4 '22 | Q3 '19 | Q2 '19 | Q1 '19 | Q4 '18 | Q3 '18 | Q2 '18 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| P/E Ratio → | -0.86 | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — |
| — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | |
| P/S Ratio | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — |
| — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | |
| P/B Ratio | 0.56 | 0.85 | 0.29 | 0.27 | 0.25 | 0.18 | 0.25 | 0.33 | 0.47 | 0.48 | — | — | — | — | — | — | — | — | — | — | — |
| — | +362.2% | +15.7% | -16.8% | -46.6% | -61.3% | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | |
| P/FCF | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — |
| — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | |
| EV / EBITDA | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — |
| — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | |
| EV / EBIT | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — |
| — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — |
Quarterly margins and returns. Watch for margin compression across consecutive quarters.
| Metric | TTM | Q2 '26 | Q1 '26 | Q4 '25 | Q3 '25 | Q2 '25 | Q1 '25 | Q4 '24 | Q3 '24 | Q2 '24 | Q1 '24 | Q4 '23 | Q3 '23 | Q2 '23 | Q4 '22 | Q3 '19 | Q2 '19 | Q1 '19 | Q4 '18 | Q3 '18 | Q2 '18 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Gross Margin | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — |
| — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | |
| Operating Margin | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — |
| — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | |
| Net Margin | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — |
| — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — |
| Metric | TTM | Q2 '26 | Q1 '26 | Q4 '25 | Q3 '25 | Q2 '25 | Q1 '25 | Q4 '24 | Q3 '24 | Q2 '24 | Q1 '24 | Q4 '23 | Q3 '23 | Q2 '23 | Q4 '22 | Q3 '19 | Q2 '19 | Q1 '19 | Q4 '18 | Q3 '18 | Q2 '18 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| ROE | -46.7% | -31.1% | -14.7% | -12.3% | -11.9% | -12.1% | -11.0% | -10.4% | -9.6% | -89.2% | — | — | — | — | -7.8% | -34.8% | -22.9% | -11.7% | -34.2% | -28.6% | -16.4% |
| — | -157.2% | -33.5% | -18.4% | -24.3% | +86.4% | — | — | — | — | — | — | — | — | +77.2% | -21.7% | -39.5% | -16.4% | +37.1% | +26.7% | +46.8% | |
| ROA | -32.0% | -22.1% | -9.1% | -7.9% | -8.0% | -8.5% | -7.9% | -8.6% | -9.1% | -11.1% | -12.5% | -8.9% | -8.8% | -10.7% | -4.5% | -30.4% | -20.2% | -10.6% | -31.8% | -26.5% | -15.4% |
| — | -161.0% | -14.8% | +8.3% | +12.3% | +24.0% | +36.6% | +2.9% | -3.0% | -3.9% | -174.9% | +70.8% | +56.3% | -0.5% | +85.7% | -14.8% | -31.0% | -14.9% | +33.2% | +21.8% | +41.5% | |
| ROIC | -31.6% | -22.4% | -8.8% | -7.6% | -7.5% | -7.8% | -7.6% | -9.2% | -10.3% | — | — | — | — | — | -6.9% | -31.4% | -22.9% | -12.9% | -39.1% | -42.6% | -34.4% |
| — | -187.3% | -15.5% | +17.3% | +26.8% | — | — | — | — | — | — | — | — | — | +82.3% | +26.3% | +33.3% | +17.8% | +30.2% | +0.5% | -8.0% |
Quarterly solvency trend — watch for debt spikes or covenant pressure.
| Metric | TTM | Q2 '26 | Q1 '26 | Q4 '25 | Q3 '25 | Q2 '25 | Q1 '25 | Q4 '24 | Q3 '24 | Q2 '24 | Q1 '24 | Q4 '23 | Q3 '23 | Q2 '23 | Q4 '22 | Q3 '19 | Q2 '19 | Q1 '19 | Q4 '18 | Q3 '18 | Q2 '18 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Debt / Equity | 0.50 | — | 0.56 | 0.50 | 0.45 | 0.40 | 0.36 | 0.32 | 0.00 | 0.00 | — | — | — | — | — | 0.08 | 0.07 | 0.07 | 0.02 | 0.01 | 0.01 |
| — | — | +57.2% | +57.2% | +61518.1% | +8541.0% | — | — | — | — | — | — | — | — | — | +493.6% | +496.2% | +356.2% | -65.2% | -24.6% | — | |
| Debt / EBITDA | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — |
| — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | |
| Current Ratio | 8.74 | 9.48 | 9.87 | 8.74 | 10.14 | 14.08 | 22.15 | 18.98 | 17.03 | 20.45 | 10.54 | 13.27 | 13.09 | 17.90 | 8.80 | 12.79 | 14.38 | 14.29 | 17.60 | 14.83 | 19.05 |
| — | -32.6% | -55.4% | -53.9% | -40.4% | -31.2% | +110.2% | +43.0% | +30.1% | +14.2% | +19.7% | +3.7% | -9.0% | +25.2% | -50.0% | -13.7% | -24.5% | -30.0% | +127.5% | +23.2% | +89.4% | |
| Quick Ratio | 8.74 | 9.48 | 9.87 | 8.74 | 10.14 | 14.08 | 22.15 | 18.98 | 17.03 | 20.45 | 10.54 | 13.27 | 13.09 | 17.90 | 8.80 | 12.79 | 14.38 | 14.29 | 17.60 | 14.83 | 19.05 |
| — | -32.6% | -55.4% | -53.9% | -40.4% | -31.2% | +110.2% | +43.0% | +30.1% | +14.2% | +19.7% | +3.7% | -9.0% | +25.2% | -50.0% | -13.7% | -24.5% | -30.0% | +127.5% | +23.2% | +89.4% | |
| Interest Coverage | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — |
| — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — |
Includes 30+ ratios · 27 years · Updated daily
Live VCP patterns, Cup & Handle overlays, support/resistance, and AI trade plans.
High-probability breakout stocks crossing their pivot across 5 pattern engines.
DCF models, multiple analysis, and analyst estimates.
10-year return with dividends reinvested.
Compare growth, multiples, and margins vs sector.
Quick answers to the most common questions about buying BOLD stock.
Boundless Bio, Inc.'s current P/E is -0.9x. Quarterly P/E ratios can vary due to seasonal revenue patterns and one-time charges.
Quarterly financial ratios reveal short-term trend shifts — margin compression, debt spikes, or valuation re-ratings — that annual figures smooth over. They're essential for active investors tracking Boundless Bio, Inc.'s business trajectory between earnings reports.